These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20945617)

  • 1. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease.
    Bobolea I; Barranco P; Fiandor A; Cabañas R; Quirce S
    J Investig Allergol Clin Immunol; 2010; 20(5):448-9. PubMed ID: 20945617
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously.
    Kamin W; Kopp MV; Erdnuess F; Schauer U; Zielen S; Wahn U
    Pediatr Allergy Immunol; 2010 Feb; 21(1 Pt 2):e160-5. PubMed ID: 19732370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of omalizumab or rhuMAB-E25 in the treatment of allergic rhinitis.
    Lee DK
    Eur Respir J; 2004 Aug; 24(2):330; author reply 330-1. PubMed ID: 15332407
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of intranasal triamcinolone acetonide on bronchial hyper-responsiveness in children with seasonal allergic rhinitis and comparison of perceptional nasal obstruction with acoustic rhinometric assessment.
    Oztürk F; Türktaş I; Asal K; Ileri F; Münevver Pinar N
    Int J Pediatr Otorhinolaryngol; 2004 Aug; 68(8):1007-15. PubMed ID: 15236886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab: a monoclonal anti-IgE antibody.
    Belliveau PP
    MedGenMed; 2005 Jan; 7(1):27. PubMed ID: 16369332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
    Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
    J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
    [No Abstract]   [Full Text] [Related]  

  • 10. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
    Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
    Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management of allergic rhinitis in children.
    Georgalas C; Terreehorst I; Fokkens W
    Pediatr Allergy Immunol; 2010 Feb; 21(1 Pt 2):e119-26. PubMed ID: 19744219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of allergic rhinitis caused by grass pollen or house-dust mites in Spain.
    Valero A; Justicia JL; Antón E; Dordal T; Fernández-Parra B; Lluch M; Montoro J; Navarro AM
    Am J Rhinol Allergy; 2011; 25(4):e123-8. PubMed ID: 21310119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desloratadine for the treatment of cypress pollen-induced allergic rhinitis.
    Demoly P; Dreyfus I; Dhivert-Donnadieu H; Mesbah K
    Ann Allergy Asthma Immunol; 2009 Sep; 103(3):260-6. PubMed ID: 19788025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin 9 in allergic rhinitis.
    Ciprandi G
    Ann Allergy Asthma Immunol; 2010 Feb; 104(2):180-1. PubMed ID: 20306823
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of nasal triamcinolone acetonide on seasonal variations of bronchial hyperresponsiveness and bronchial inflammation in nonasthmatic children with seasonal allergic rhinitis.
    Orhan F; Sekerel BE; Adalioglu G; Pinar M; Tuncer A
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):438-45. PubMed ID: 15104196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic rhinitis and childhood sleep disordered breathing.
    Dosanjh A
    Allergol Immunopathol (Madr); 2009; 37(3):171-2. PubMed ID: 19769853
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab (Xolair): an anti-IgE antibody for asthma.
    Med Lett Drugs Ther; 2003 Aug; 45(1163):67-8. PubMed ID: 12915804
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
    Adelroth E; Rak S; Haahtela T; Aasand G; Rosenhall L; Zetterstrom O; Byrne A; Champain K; Thirlwell J; Cioppa GD; Sandström T
    J Allergy Clin Immunol; 2000 Aug; 106(2):253-9. PubMed ID: 10932067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe life-threatening asthma precipitated by a topical nonsteroidal anti-inflammatory drug.
    Foong NZE; Yii ACA; Hsu AAL
    Ann Allergy Asthma Immunol; 2018 May; 120(5):535-536. PubMed ID: 29573959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.